Easing the Bottleneck - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Easing the Bottleneck
Manufacturers of therapeutic monoclonal antibodies consider new paradigms in purification technologies.


Pharmaceutical Technology
Volume 33, Issue 5, pp. 44-50

Gunter Jagschies, senior director of strategic customer relations at GE Healthcare BioSciences in Uppsala, Sweden, is less swayed by stories of bottlenecks. "You hear these stories, and at the same time, they seem to come down to existing installations built with too small downstream processing equipment to accommodate very much higher productivity upstream. This is not so much a problem of the technology but more of the ability to predict what would happen with cell culture," he says. Jagschies points to case studies that indicate that 10 metric tons of product—roughly 10 times today's highest production levels—can be made with existing technologies. The problem, as he sees it, has to do with the rate at which high-yield supernatants can be run through a column.

"You have to process monoclonal antibodies quickly," says Jagschies. "There are problems maintaining the antibodies' stability in liquid." The protein product is vulnerable to enzymatic degradation by proteases, with the result that the composition of a batch at the end of an 18-hour holding period may differ from the starting composition. Theoretically, product yields could become so high as to require several days to purify the contents of just one bioreactor. "But no one is there yet. Current [purification] technologies can handle a batch in 12 to 18 hours," Jagschies says.

Ironically, the purification problem may be more acute for contract manufacturers and niche manufacturers, who are producing the smallest product quantities. Current blockbusters—Genentech's anticancer drug Rituxan (rituximab), for example, or Abbott's arthritis drug Humira (adalimumab)—enjoy billion-dollar sales because they address diseases with large patient populations. But the day of the blockbuster may be over—even for the relatively new mAb drugs.

In coming years, niche drugs for relatively rare conditions, or targeted therapeutics that are effective for subpopulations of patients suffering from fairly common conditions such as arthritis, will require much smaller production batches to serve the reduced markets. But smaller batches may mean very expensive purification equipment that is not used to its maximal capacity or for its total life span, which raises the the cost per use of such equipment. Even producers of blockbusters are looking for lower-cost options as pressure increases on them to lower drug prices, and as they stare down the specter of competition from follow-on biologics. In fact, cost considerations have been as much of a driver of innovation as the high product yields.

Focus on capture

Of the steps in mAb purification, the capture step receives the most attention, possibly because it's so important in trapping the product, but also possibly because of the expense associated with it. Standard protocol relies heavily on the affinity of human antibodies for a compound called Protein A.

In the early years of antibody purification, manufacturers relied on "natural" Protein A; that is, the protein as it was isolated from the cell walls of the bacterium Staphylococcus aureus. These days, most commercially available Protein A has been genetically engineered and molecularly cloned. As used in a chromatography column, Protein A is part of a resin. Resins from different vendors differ markedly to respond to the distinctive needs of their customers, but they all share some common features. In general, this resin consists of some kind of porous bead inside of which is a gelatinous matrix to which the Protein A is chemically affixed. The antibody product is poured through the chromatography column, diffuses inside the beads and through the gelatinous matrix where it finds and binds to Protein A. Almost all of the contaminants, most of which do not have an affinity for Protein A or the resin components, exit the column. In subsequent steps, buffers are run through the column to release the antibody product from Protein A, and the now somewhat purified product is collected and shunted into subsequent "polishing" steps.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here